A synthetic peptide from human Neutrophil Elastase
A synthesized peptide derived from Human Nexilin.
A synthesized peptide derived from human NF1, corresponding to a region within C-terminal amino acids.
This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene.NF1 (Neurofibromin 1) is a Protein Coding gene. Diseases associated with NF1 include Neurofibromatosis-Noonan Syndrome and Neurofibromatosis, Type 1. Among its related pathways are Development VEGF signaling via VEGFR2 - generic cascades and RET signaling. GO annotations related to this gene include binding and phosphatidylcholine binding.
A synthesized peptide derived from human NF2 / Merlin, corresponding to a region within N-terminal amino acids.
A synthesized peptide derived from human NF2 / Merlin, corresponding to a region within C-terminal amino acids.
Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway,a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex.
Inserisci la tua e-mail e seleziona le aree di interesse per ricevere le ultime novità, approfondimenti e promozioni.
Seleziona uno o più ambiti di interesse per ricevere comunicazioni più utili e mirate.
2025 TEMA Ricerca - All Rights Reserved.
